Pexidartinib
Modify Date: 2025-08-20 11:43:07
Pexidartinib structure
|
Common Name | Pexidartinib | ||
|---|---|---|---|---|
| CAS Number | 1029044-16-3 | Molecular Weight | 417.815 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 580.0±50.0 °C at 760 mmHg | |
| Molecular Formula | C20H15ClF3N5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 304.6±30.1 °C | |
Use of PexidartinibPexidartinib (PLX-3397) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13 nM, 27 nM, and 11 nM for CSF1R, c-Kit, and FLT3, respectively. |
| Name | Pexidartinib |
|---|---|
| Synonym | More Synonyms |
| Description | Pexidartinib (PLX-3397) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13 nM, 27 nM, and 11 nM for CSF1R, c-Kit, and FLT3, respectively. |
|---|---|
| Related Catalog | |
| Target |
IC50: 28 nM (c-Fms), 16 nM (c-Kit) |
| In Vivo | Pexidartinib is a potent drug for treatment of cancer and used for Phase III TGCT clinical trial[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 580.0±50.0 °C at 760 mmHg |
| Molecular Formula | C20H15ClF3N5 |
| Molecular Weight | 417.815 |
| Flash Point | 304.6±30.1 °C |
| Exact Mass | 417.096802 |
| PSA | 66.49000 |
| LogP | 4.77 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.662 |
| Storage condition | -20℃ |
| Hazard Codes | N |
|---|
| PLX3397 |
| 5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-{[6-(trifluoromethyl)-3-pyridinyl]methyl}-2-pyridinamine |
| 3-Pyridinemethanamine, N-[5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)- |
| N-[5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-3-pyridinemethanamine |
| PLX-3397 |
| pexidartinib |